Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Strong blockbuster sales boost Bloomsbury

(Sharecast News) - Bloomsbury Publishing said on Wednesday that full-year results were on track to meet targets, driven by the ongoing popularity of blockbuster authors such as Sarah J Maas and JK Rowling. Updating investors ahead of its annual general meeting, the Harry Potter publisher said its consumer division had benefited in particular from the paperback launch of Maas' House of Flame and Shadow in June.

The fantasy booked topped the bestseller lists in both the UK and US.

In addition, it noted that Rowling's Pocket Potters series would launch in August, alongside a "strong" front list for the remainder of the year.

Pocket Potters are mini guides to all the main characters featured in the enduringly popular wizardry series.

In its non-consumer division, meanwhile, Bloomsbury said the integration of Rowman & Littlefield was continuing, with over 5,300 titles now digitised.

Bloomsbury announced last year it was buying the American publisher's academic business in an $83m deal, its largest acquisition to date.

As a result, the firm - which publishes interim numbers in October - said it expected full-year results to be in line with consensus.

The market has currently pencilled in pre-tax profits, before one-off costs, of £41.6m on revenues of £335.9m for the year to 28 February 2025.

Bloomsbury concluded: "We continue to execute our Bloomsbury 2030 vision focused on our growth, portfolio and people. The resilience of our business created through the portfolio of portfolios strategy underpins the confidence our board has in our future."

As at 0830 BST, shares in the FTSE 250 firm were 1% higher at 492.35p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.